March 24, 2026

Mammography AI Spots Vascular Signals

Routine breast imaging offers opportunity for cardiovascular risk assessment.

Conexiant

March 24, 2026

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Conexiant

March 23, 2026

Metabolic Acidosis Care Limited in Chronic Kidney Disease

Low testing rates may contribute to underdiagnosis and undertreatment in Japan

Conexiant

March 20, 2026

Healthy Lifestyle Lowers Cardiometabolic Risk in Hypertension

Sustained and improved behaviors following diagnosis tied to lower cardiometabolic risk, highlighting an underused opportunity in care

Conexiant

March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant

March 19, 2026

PREVENT Equations Show How Age, Risk Factors Shape CVD Risk

Systematic analysis demonstrates how kidney disease, diabetes, and other factors accelerate 10-year cardiovascular risk, helping guide clinician–patient prevention discussions.

Conexiant

March 18, 2026

Premature Menopause Tied to Higher Lifetime CHD Risk

Lifetime risk estimates evaluated by menopause timing.

Conexiant

March 18, 2026

Medical Oddities: Friends, Family… and Faster Aging?

From gut gas trackers to bat vaccines, relationships and aging, GLP-1 hair shifts, and bug-based delivery—medicine keeps getting creative.

Conexiant

March 18, 2026

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

Conexiant

March 18, 2026

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

Conexiant